IP Library Granted Patent US 9,066,851
Granted Patent B2
US 9,066,851 · App. 13/132,855 · Granted Jun 30, 2015

Extended length botulinum toxin formulation for human or mammalian use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,066,851
App. No.
13/132,855
Granted
Jun 30, 2015
Kind
B2
Abstract

An extended duration pharmaceutical composition including a botulinum neurotoxin, an adhesive agent, and a stabilizing macromolecule. The composition effectively has all the properties to cause chemodenervation through a facial muscle, or other muscle, that predecessor botulinum toxin preparations have had as well as agents which create a fibrotic adhesion on the under surface of facial muscles (or other muscles) to the facial bone (or other bones) so that the facial bone tethers the under surface of the facial muscle, thereby causing fibrosis to the underlying fat pad. The composition can be used to treat various disorders. Methods of modifying facial contour for functional or cosmetic purposes in a human patient are disclosed which involve injecting a therapeutically effective amount of the disclosed compositions. A method of quantifying the extended duration of the compositions is also disclosed.

Claims (6)

1. A pharmaceutical composition comprising a botulinum neurotoxin, an adhesive agent, and one or more stabilizing macromolecules, wherein the adhesive agent is a sequentially or simultaneously administered preparation containing fibrinogen and thrombin, and wherein the one or more stabilizing macromolecules comprises a stabilizing polysaccharide.

2. The pharmaceutical composition of claim 1 , wherein the one or more stabilizing macromolecules further comprises fibrinogen.

3. The pharmaceutical composition of claim 1 , wherein the one or more stabilizing macromolecules further comprises thrombin.

4. The pharmaceutical composition of claim 1 , wherein the botulinum neurotoxin, the adhesive agent, and the stabilizing macromolecule are not premixed, thereby allowing sequential delivery.

5. The pharmaceutical composition of claim 1 , wherein the adhesive agent is a sequentially administered preparation containing fibrinogen and thrombin.

6. The pharmaceutical composition of claim 1 , wherein the adhesive agent is a simultaneously administered preparation containing fibrinogen and thrombin.

Assignments (7)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 038870/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2011
From: BORODIC, GARY E.
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 027218/0618 →